The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Table 5 Multivariate Cox proportional hazard regression analysis for overall survival and relapse-free survival in stage I and II osteosarcoma patients

Characteristics	OS	P	RFS	P
Characteristics	HR (95% CI)	P	HR (95% CI)	P
Multivariate analysis Model 1^a
Tumor size, cm, > 8 (vs. ≤ 8)	4.617 (1.251–17.038)	0.022	3.188 (0.982–10.349)	0.054
BRCA1, positive (vs. negative)			4.257 (1.024–17.696)	0.046
γH2AX, positive (vs. negative)	19.634 (2.412–159.853)	0.005	6.366 (1.203–33.695)	0.029
Multivariate analysis Model 2^b
CSddrm, score 3–4 (vs. score 0–2)	30.043 (3.724–242.374)	0.001	27.986 (3.501–223.717)	0.002

OS overall survival, RFS relapse-free survival, HR hazard ratio, 95% CI 95% confidence interval, CSddrm the combined score for the immunohistochemical expression of PARP1, γH2AX, BRCA1, and BRCA2
^aVariables considered in multivariate analysis Model 1 were tumor size, tumor stage, histologic grade, and the expression of PARP1, γH2AX, BRCA1, and BRCA2
^bVariables considered in multivariate analysis Model 2 were tumor size, tumor stage, histologic grade, and CSddrm

ISSN: 1756-9966